82 results on '"Alice Norton"'
Search Results
2. Scoping review protocol on research prioritisation for preparedness and response to outbreaks of high consequence pathogens [version 2; peer review: 3 approved]
- Author
-
Shanthi Levanita, Dorothy Chepkirui, Isabel Foster, Susan Khader Ibrahim, Louise Sigfrid, Eli Harriss, Alice Norton, and Emilia Antonio
- Subjects
High consequence pathogens ,Preparedness ,Response ,Priority pathogens ,Research prioritisation ,eng ,Science ,Social Sciences - Abstract
Background Prioritisation of research activities for infectious disease pathogens is usually undertaken through the identification of important research and knowledge gaps. Research prioritisation is an essential element of both effective responses to disease outbreaks and adequate preparedness. There is however currently no published mapping of activities on and evidence from research prioritisation for high consequence pathogens. The objectives of this review are to map all published research prioritisation exercises on high-consequence pathogens; provide an overview of methodologies employed for prioritising research for these pathogens; describe monitoring and evaluation processes for research areas prioritised; and identify any standards and guidance for effectively undertaking research prioritisation activities for high consequence pathogens. Methods The Joanna Briggs Institute guidance of scoping review conduct will be used. The search will be undertaken using the key terms of “research prioritisation”, “response”, “control”, and related terms, and a list of high-consequence pathogens derived from WHO (2020), EMERGE (2019), Europe CDC (2022) and the Association of Southeast Asian Nations (2021). We will search WHO Global Index Medicus; Ovid Medline; Ovid Embase; Ovid Global Health; and Scopus. Backward citations review of the included full text documents will also be conducted. Google Scholar and Overton will be searched for grey literature. Two independent reviewers will screen the retrieved documents using Rayyan and extract data in a data extraction template in Microsoft Excel 2021. Screening results will be presented using the PRISMA-ScR template with narrative synthesis undertaken for the extracted data. Conclusion This review will map existing research priorities for high consequence pathogens. Further, it will provide an understanding of methodologies used for prioritisation, processes for monitoring and evaluation of progress made against research agendas, and evidence on standards that could be recommended for effective prioritisation of research for high consequence pathogens.
- Published
- 2024
- Full Text
- View/download PDF
3. Mapping regional funding for COVID-19 research in the Asia-Pacific region
- Author
-
Alice Norton, Emilia Antonio, Jieun Lee, Nicolas Pulik, Tanu Soni, Hans-Eckhardt Hagen, and Choong-Min Ryu
- Subjects
Medicine (General) ,R5-920 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Introduction The Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) is a network of funders supporting research on infectious diseases of epidemic/pandemic potential. GloPID-R is establishing regional hubs to strengthen stakeholder engagement particularly among low-income and middle-income countries. The first pilot hub, led from Republic of Korea (South Korea), has been launched in the Asia-Pacific region, a region highly prone to outbreaks of emerging infectious diseases. We present findings of mapping research undertaken in support of the hub’s development.Methods We analysed five COVID-19 research databases in September 2022 to identify research funders and intermediary funding sources supporting research in infectious diseases in the Asia-Pacific region. This was complemented with an in-depth analysis of the UK Collaborative on Development Research (UKCDR) and GloPID-R COVID-19 Research Project Tracker to assess the alignment of funded projects in the region to the WHO COVID-19 research priorities.Results We identified 453 funders and funding sources supporting COVID-19 research in the Asia-Pacific Region including public, private and philanthropic organisations and universities. However, these organisations were clustered in few countries in the region. The in-depth analysis of the UKCDR and GloPID-R COVID-19 Research project Tracker found limited research involving Asia-Pacific countries with the 117 funders supporting these projects investing at least US$604m in COVID-19 research in the region. Social Sciences was the dominant theme on which funded projects focused whereas the priority areas with the least number of projects were research on ‘animal and environmental health’ and ‘ethics considerations for research’.Conclusion Our analyses show the diversity of funding sources for research on infectious diseases in the Asia-Pacific region. Engagement between multiple actors in the health research system is likely to promote enhanced coordination for greater research impact. GloPID-R’s Asia-Pacific regional hub aims to support activities for the enhancement of preparedness for outbreaks of emerging infectious diseases in the region.
- Published
- 2023
- Full Text
- View/download PDF
4. A living mapping review for COVID-19 funded research projects: final (27 month) update [version 10; peer review: 2 approved]
- Author
-
Sheila Mburu, Henrike Grund, Genevieve Boily-Larouche, Laura Scott, Emma Clegg, Marta Tufet Bayona, Marguerite Gollish, Morgan Lay, Sara Sahota, Nusrat Jabin, Cathryn Johnston, Andrea Padilla, Meron Kifle, Chantel Jones, Adrian Bucher, Susan Khader, Alice Norton, Nicole Advani, and Emilia Antonio
- Subjects
Living systematic review ,COVID-19 ,Coronavirus ,research funding ,coordination ,global health policy ,eng ,Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th October 2022 the database contains 20,006 projects, funded by 351 funders, taking place across 157 countries representing an investment of at least $7.4 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open, accessible, and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analyses are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this final version ten analysis, we provide an updated detailed descriptive analysis of the database (on data from three months after version nine) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations, and research locations (with a focus on resource-limited countries). Conclusions: As the global research response to COVID-19 plateaus, this living mapping review has helped both funders and researchers to prioritise resources and review investments.
- Published
- 2023
- Full Text
- View/download PDF
5. The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Author
-
Valeria Ceolin, Sae Ishimaru, Seth E. Karol, Francisco Bautista, Bianca Frederika Goemans, Gwenaëlle Gueguen, Marieke Willemse, Laura Di Laurenzio, Jennifer Lukin, Harm van Tinteren, Franco Locatelli, Arnaud Petit, Daisuke Tomizawa, Alice Norton, Gertjan Kaspers, Dirk Reinhardt, Sarah K. Tasian, Gwen Nichols, Edward Anders Kolb, Christian Michel Zwaan, and Todd Michael Cooper
- Subjects
acute myeloid leukemia ,clinical trials ,pediatric ,refractory/relapsed ,PedAL ,EuPAL ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The prognosis of children with acute myeloid leukemia (AML) has improved incrementally over the last few decades. However, at relapse, overall survival (OS) is approximately 40–50% and is even lower for patients with chemo-refractory disease. Effective and less toxic therapies are urgently needed for these children. The Pediatric Acute Leukemia (PedAL) program is a strategic global initiative that aims to overcome the obstacles in treating children with relapsed/refractory acute leukemia and is supported by the Leukemia and Lymphoma Society in collaboration with the Children’s Oncology Group, the Innovative Therapies for Children with Cancer consortium, and the European Pediatric Acute Leukemia (EuPAL) foundation, amongst others. In Europe, the study is set up as a complex clinical trial with a stratification approach to allocate patients to sub-trials of targeted inhibitors at relapse and employing harmonized response and safety definitions across sub-trials. The PedAL/EuPAL international collaboration aims to determine new standards of care for AML in a first and second relapse, using biology-based selection markers for treatment stratification, and deliver essential data to move drugs to front-line pediatric AML studies. An overview of potential treatment targets in pediatric AML, focused on drugs that are planned to be included in the PedAL/EuPAL project, is provided in this manuscript.
- Published
- 2023
- Full Text
- View/download PDF
6. Severe acute hepatitis of unknown aetiology in children—what is known?
- Author
-
Susan Khader, Isabel Foster, Andrew Dagens, Alice Norton, and Louise Sigfrid
- Subjects
Acute severe hepatitis of unknown origin ,Paediatrics ,Child health ,Preparedness ,Outbreak response ,Global health ,Medicine - Abstract
Abstract The ongoing investigations into clusters of children affected by severe acute hepatitis of unknown aetiology have put our global capacity for a coordinated, effective response to the test. The global health community have rapidly convened to share data and inform the response. In the UK, where most cases were initially identified, a coordinated public health and clinical research response was rapidly initiated. Since then, cases have been reported from other countries, predominantly from higher-income countries. While agencies are keeping an open mind to the cause, the working hypothesis and case notifications raise important questions about our capacity to detect emerging cases in lower-resourced settings with a recognised lack of access to diagnostics even for commonly circulating viruses such as hepatitis A. The limited capability to generate integrated global pathogen surveillance data is a challenge for the outbreak investigations, highlighting an urgent need to strengthen access to diagnostics, with a focus on lower-resourced settings, to improve the capacity to detect emerging diseases to inform care and to improve outcomes and outbreak control.
- Published
- 2022
- Full Text
- View/download PDF
7. A living mapping review for COVID-19 funded research projects: two year update [version 9; peer review: 2 approved]
- Author
-
Sheila Mburu, Henrike Grund, Genevieve Boily-Larouche, Laura Scott, Emma Clegg, Marta Tufet Bayona, Marguerite Gollish, Morgan Lay, Sara Sahota, Nusrat Jabin, Cathryn Johnston, Meron Kifle, Chantel Jones, Adrian Bucher, Susan Khader, Alice Norton, Nicole Advani, and Emilia Antonio
- Subjects
Living systematic review ,COVID-19 ,Coronavirus ,research funding ,coordination ,global health policy ,eng ,Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th July 2022 the database contains 17,955 projects, funded by 345 funders, taking place across 157 countries representing an investment of at least $6.5 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version nine analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version eight) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources and review investments.
- Published
- 2023
- Full Text
- View/download PDF
8. Scoping review protocol on research prioritisation for preparedness and response to outbreaks of high consequence pathogens [version 1; peer review: 2 approved]
- Author
-
Shanthi Levanita, Dorothy Chepkirui, Isabel Foster, Susan Khader Ibrahim, Louise Sigfrid, Eli Harriss, Alice Norton, and Emilia Antonio
- Subjects
High consequence pathogens ,Preparedness ,Response ,Priority pathogens ,Research prioritisation ,eng ,Science ,Social Sciences - Abstract
Background: Prioritisation of research activities for infectious disease pathogens is usually undertaken through the identification of important research and knowledge gaps. Research prioritisation is an essential element of both effective responses to disease outbreaks and adequate preparedness. There is however currently no published mapping of activities on and evidence from research prioritisation for high consequence pathogens. The objectives of this review are to map all published research prioritisation exercises on high-consequence pathogens; provide an overview of methodologies employed for prioritising research for these pathogens; describe monitoring and evaluation processes for research areas prioritised; and identify any standards and guidance for effectively undertaking research prioritisation activities for high consequence pathogens. Methods: The Joanna Briggs Institute guidance of scoping review conduct will be used. The search will be undertaken using the key terms of “research prioritisation”, “response”, “control”, and related terms, and a list of high-consequence pathogens derived from WHO (2020), EMERGE (2019), Europe CDC (2022) and the Association of Southeast Asian Nations (2021). We will search WHO Global Index Medicus; Ovid Medline; Ovid Embase; Ovid Global Health; and Scopus. Backward citations review of the included full text documents will also be conducted. Google Scholar and Overton will be searched for grey literature. Two independent reviewers will screen the retrieved documents using Rayyan and extract data in a data extraction template in Microsoft Excel 2021. Screening results will be presented using the PRISMA-ScR template with narrative synthesis undertaken for the extracted data. Conclusion: This review will map existing research priorities for high consequence pathogens. Further, it will provide an understanding of methodologies used for prioritisation, processes for monitoring and evaluation of progress made against research agendas, and evidence on standards that could be recommended for effective prioritisation of research for high consequence pathogens.
- Published
- 2023
- Full Text
- View/download PDF
9. Sudan virus disease outbreak in Uganda: urgent research gaps
- Author
-
Duduzile Edith Ndwandwe, Alice Norton, Susan Khader Ibrahim, and Katherina Thomas
- Subjects
Medicine (General) ,R5-920 ,Infectious and parasitic diseases ,RC109-216 - Abstract
The Sudan ebolavirus (SUDV) outbreak highlights our ongoing vulnerability to re-emerging high-consequence infectious diseases. Although the Minister of health in Uganda has initiated public health measures in collaboration with neighbouring countries and with support of the WHO, cases have continued to spread to several regions including the capital. The ongoing transmission, uncertain case numbers and no licensed vaccine or therapeutics available are a cause for concern. We searched four databases for SUDV research using the search terms “SUDV”, “Sudan Virus” and “Ebola Sudan”. Our analysis identified only 20 SUDV research studies. Most were implemented in the USA and only one in Uganda. Nine studies were on therapeutics, eight on vaccines, one on diagnostics, one in one health and one in social science. Our data highlight a lack of SUDV research and an urgent need for investment to identify an effective vaccine, and optimal supportive care and therapeutic strategies for all at risk groups as a key research priority. Research investments should be prioritised into vaccines and treatment strategies that will be accessible to high-risk populations in affected regions during the outbreak, to protect populations, improve individual outcomes and facilitate outbreak control.
- Published
- 2022
- Full Text
- View/download PDF
10. A living mapping review for COVID-19 funded research projects: 21 month update [version 8; peer review: 2 approved]
- Author
-
Sheila Mburu, Henrike Grund, Genevieve Boily-Larouche, Laura Scott, Emma Clegg, Marta Tufet Bayona, Marguerite Gollish, Morgan Lay, Sara Sahota, Nusrat Jabin, Cathryn Johnston, Meron Kifle, Chantel Jones, Adrian Bucher, Susan Khader, Alice Norton, Nicole Advani, and Emilia Antonio
- Subjects
Living systematic review ,COVID-19 ,Coronavirus ,research funding ,coordination ,global health policy ,eng ,Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th April 2022 the database contains 16,353 projects, funded by 319 funders, taking place across 157 countries representing an investment of at least $6.2 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version eight analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version seven) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2022
- Full Text
- View/download PDF
11. A living mapping review for COVID-19 funded research projects: 18 month update [version 7; peer review: 2 approved]
- Author
-
Sheila Mburu, Henrike Grund, Genevieve Boily-Larouche, Laura Scott, Emma Clegg, Marta Tufet Bayona, Marguerite Gollish, Morgan Lay, Sara Sahota, Nusrat Jabin, Cathryn Johnston, Meron Kifle, Chantel Jones, Adrian Bucher, Susan Khader, Alice Norton, Nicole Advani, and Emilia Antonio
- Subjects
Living systematic review ,COVID-19 ,Coronavirus ,research funding ,coordination ,global health policy ,eng ,Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th January 2022 the database contains 14,778 projects, funded by 306 funders, taking place across 157 countries representing an investment of at least $5.7 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version seven analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version six) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2022
- Full Text
- View/download PDF
12. Availability, scope and quality of monkeypox clinical management guidelines globally: a systematic review
- Author
-
Helen Groves, Dania Dahmash, Shevin T Jacob, Peter W Horby, Louise Sigfrid, Andrew Dagens, Erhui Cai, Ishmeala Rigby, Tom Fletcher, Lucille Blumberg, Alice Norton, Muge Cevik, Keerti Gedela, Melina Michelen, Vincent Cheng, Eli Harriss, Eika Webb, Amanda M Rojek, Susan Khader, Samuel Lipworth, Robert Nartowski, and Peter Hart
- Subjects
Medicine (General) ,R5-920 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background Monkeypox (MPX) is an important human Orthopoxvirus infection. There has been an increase in MPX cases and outbreaks in endemic and non-endemic regions in recent decades. We appraised the availability, scope, quality and inclusivity of clinical management guidelines for MPX globally.Methods For this systematic review, we searched six databases from inception until 14 October 2021, augmented by a grey literature search until 17 May 2022. MPX guidelines providing treatment and supportive care recommendations were included, with no exclusions for language. Two reviewers assessed the guidelines. Quality was assessed using the Appraisal of Guidelines for Research and Evaluation II tool.Results Of 2026 records screened, 14 guidelines were included. Overall, most guidelines were of low-quality with a median score of 2 out of 7 (range: 1–7), lacked detail and covered a narrow range of topics. Most guidelines focused on adults, five (36%) provided some advice for children, three (21%) for pregnant women and three (21%) for people living with HIV. Treatment guidance was mostly limited to advice on antivirals; seven guidelines advised cidofovir (four specified for severe MPX only); 29% (4/14) tecovirimat, and 7% (1/14) brincidofovir. Only one guideline provided recommendations on supportive care and treatment of complications. All guidelines recommended vaccination as post-exposure prophylaxis (PEP). Three guidelines advised on vaccinia immune globulin as PEP for severe cases in people with immunosuppression.Conclusion Our results highlight a lack of evidence-based clinical management guidelines for MPX globally. There is a clear and urgent need for research into treatment and prophylaxis including for different risk populations. The current outbreak provides an opportunity to accelerate this research through coordinated high-quality studies. New evidence should be incorporated into globally accessible guidelines, to benefit patient and epidemic outcomes. A ‘living guideline’ framework is recommended.PROSPERO registration number CRD42020167361.
- Published
- 2022
- Full Text
- View/download PDF
13. A living mapping review for COVID-19 funded research projects: 15 month update [version 6; peer review: 2 approved]
- Author
-
Sheila Mburu, Henrike Grund, Genevieve Boily-Larouche, Laura Scott, Emma Clegg, Marta Tufet Bayona, Marguerite Gollish, Morgan Lay, Sara Sahota, Nusrat Jabin, Cathryn Johnston, Meron Kifle, Chantel Jones, Adrian Bucher, Susan Khader, Alice Norton, Nicole Advani, and Emilia Antonio
- Subjects
Living systematic review ,COVID-19 ,Coronavirus ,research funding ,coordination ,global health policy ,eng ,Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global nature of the pandemics. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th October 2021 the database contains 13,484 projects, funded by 285 funders, taking place across 156 countries representing an investment of at least $5.1 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version six analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version five) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2022
- Full Text
- View/download PDF
14. A living mapping review for COVID-19 funded research projects: one year update [version 5; peer review: 2 approved]
- Author
-
Sheila Mburu, Henrike Grund, Genevieve Boily-Larouche, Laura Scott, Emma Clegg, Marta Tufet Bayona, Marguerite Gollish, A. Morgan Lay, Sara Sahota, Gail Carson, Nusrat Jabin, Cathryn Johnston, Adrian Bucher, Alice Norton, Nicole Advani, and Emilia Antonio
- Subjects
Living systematic review ,COVID-19 ,Coronavirus ,research funding ,coordination ,global health policy ,eng ,Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th July 2021 the database contains 12,419 projects, funded by 255 funders, taking place across 149 countries representing an investment of at least $4.9 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version five analysis we provide an updated detailed descriptive analysis of the database (three months after version four) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2022
- Full Text
- View/download PDF
15. Preparing for a pandemic: highlighting themes for research funding and practice—perspectives from the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)
- Author
-
Alice Norton, Louise Sigfrid, Adeniyi Aderoba, Naima Nasir, Peter G. Bannister, Shelui Collinson, James Lee, Geneviève Boily-Larouche, Josephine P. Golding, Evelyn Depoortere, Gail Carson, Barbara Kerstiëns, and Yazdan Yazdanpanah
- Subjects
Pandemic ,Epidemic ,Preparedness ,COVID-19 ,Cohorts ,Clinical trials ,Medicine - Published
- 2020
- Full Text
- View/download PDF
16. A living mapping review for COVID-19 funded research projects: nine-month update [version 4; peer review: 2 approved]
- Author
-
Alice Norton, Adrian Bucher, Emilia Antonio, Nicole Advani, Henrike Grund, Sheila Mburu, Emma Clegg, Marguerite Gollish, Nusrat Jabin, Laura Scott, Genevieve Boily-Larouche, A. Morgan Lay, Gail Carson, and Marta Tufet Bayona
- Subjects
Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th April 2021 the database contains 10,608 projects, funded by 201 funders, taking place across 142 countries representing an investment of at least $4.7 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version four analysis we provide an updated detailed descriptive analysis of the database (three months after version three) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2021
- Full Text
- View/download PDF
17. A living mapping review for COVID-19 funded research projects: three-month update [version 2; peer review: 2 approved]
- Author
-
Alice Norton, Adrian Bucher, Emilia Antonio, Nicole Advani, Henrike Grund, Sheila Mburu, Emma Clegg, Laura Scott, Genevieve Boily-Larouche, A. Morgan Lay, Gail Carson, and Marta Tufet Bayona
- Subjects
Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th October 2020 the database contains 5,084 projects, funded by 71 funders, taking place across 134 countries representing an investment of at least $1.7 billion. To our knowledge it is one of the most comprehensive databases, covering a wide breadth of research disciplines. The database is aligned to the World Health Organisation (WHO) Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this three-month update analysis we provide an updated detailed descriptive analysis of the database and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: This living mapping review will help both funders and researchers to prioritise resources to underfunded areas where there is greatest research need and facilitate further strategic collaboration.
- Published
- 2020
- Full Text
- View/download PDF
18. Funding and COVID-19 research priorities - are the research needs for Africa being met? [version 1; peer review: 2 approved]
- Author
-
Emilia Antonio, Moses Alobo, Marta Tufet Bayona, Kevin Marsh, and Alice Norton
- Subjects
Medicine ,Science - Abstract
Background: Emerging data from Africa indicates remarkably low numbers of reported COVID-19 deaths despite high levels of disease transmission. However, evolution of these trends as the pandemic progresses remains unknown. More certain are the devastating long-term impacts of the pandemic on health and development evident globally. Research tailored to the unique needs of African countries is crucial. UKCDR and GloPID-R have launched a tracker of funded COVID-19 projects mapped to the WHO research priorities and research priorities of Africa and less-resourced countries and published a baseline analysis of a living systematic review (LSR) of these projects. Methods: In-depth analyses of the baseline LSR for COVID-19 funded research projects in Africa (as of 15th July 2020) to determine the funding landscape and alignment of the projects to research priorities of relevance to Africa. Results: The limited COVID-19 related research across Africa appears to be supported mainly by international funding, especially from Europe, although with notably limited funding from United States-based funders. At the time of this analysis no research projects funded by an African-based funder were identified in the tracker although there are several active funding calls geared at research in Africa and there may be funding data that has not been made publicly available. Many projects mapped to the WHO research priorities and five particular gaps in research funding were identified, namely: investigating the role of children in COVID-19 transmission; effective modes of community engagement; health systems research; communication of uncertainties surrounding mother-to-child transmission of COVID-19; and identifying ways to promote international cooperation. Capacity strengthening was identified as a dominant theme in funded research project plans. Conclusions: We found significantly lower funding investments in COVID-19 research in Africa compared to high-income countries, seven months into the pandemic, indicating a paucity of research targeting the research priorities of relevance to Africa.
- Published
- 2020
- Full Text
- View/download PDF
19. Baseline results of a living systematic review for COVID-19 funded research projects [version 1; peer review: 2 approved]
- Author
-
Alice Norton, Adrian Bucher, Emilia Antonio, Nicole Advani, Henrike Grund, Sheila Mburu, Emma Clegg, Genevieve Boily-Larouche, A. Morgan Lay, Gail Carson, and Marta Tufet Bayona
- Subjects
Medicine ,Science - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th July 2020 the database contains 1,858 projects, funded by 25 funders, taking place across 102 countries. To our knowledge it is one of the most comprehensive databases, covering a wide breadth of research disciplines. The database is aligned to the World Health Organisation (WHO) Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living systematic review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this baseline analysis we provide the first detailed descriptive analysis of the database and focus our thematic analysis on research gaps, study populations and research locations (with a focus on resource-limited countries). Conclusions: This living systematic review will help both funders and researchers to prioritise resources to underfunded areas where there is greatest research need and facilitate further strategic collaboration.
- Published
- 2020
- Full Text
- View/download PDF
20. The remaining unknowns: a mixed methods study of the current and global health research priorities for COVID-19
- Author
-
Peter Piot, Trudie Lang, Alice Norton, Arancha De La Horra Gozalo, Nicole Feune de Colombi, Moses Alobo, Juliette Mutheu Asego, Zainab Al-Rawni, Emilia Antonio, James Parker, Wayne Mwangi, Colette Adhiambo Wesonga, Kevin Marsh, and Marta Tufet
- Subjects
Medicine (General) ,R5-920 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Introduction In March 2020, the WHO released a Global Research Roadmap in an effort to coordinate and accelerate the global research response to combat COVID-19 based on deliberations of 400 experts across the world. Three months on, the disease and our understanding have both evolved significantly. As we now tackle a pandemic in very different contexts and with increased knowledge, we sought to build on the work of the WHO to gain a more current and global perspective on these initial priorities.Methods We undertook a mixed methods study seeking the views of the global research community to (1) assess which of the early WHO roadmap priorities are still most pressing; (2) understand whether they are still valid in different settings, regions or countries; and (3) identify any new emerging priorities.Results Thematic analysis of the significant body of combined data shows the WHO roadmap is globally relevant; however, new important priorities have emerged, in particular, pertinent to low and lower middle-income countries (less resourced countries), where health systems are under significant competing pressures. We also found a shift from prioritising vaccine and therapeutic development towards a focus on assessing the effectiveness, risks, benefits and trust in the variety of public health interventions and measures. Our findings also provide insight into temporal nature of these research priorities, highlighting the urgency of research that can only be undertaken within the period of virus transmission, as well as other important research questions but which can be answered outside the transmission period. Both types of studies are key to help combat this pandemic but also importantly to ensure we are better prepared for the future.Conclusion We hope these findings will help guide decision-making across the broad research system including the multilateral partners, research funders, public health practitioners, clinicians and civil society.
- Published
- 2020
- Full Text
- View/download PDF
21. Characterization of leukemias with ETV6-ABL1 fusion
- Author
-
Marketa Zaliova, Anthony V. Moorman, Giovanni Cazzaniga, Martin Stanulla, Richard C. Harvey, Kathryn G. Roberts, Sue L. Heatley, Mignon L. Loh, Marina Konopleva, I-Ming Chen, Olga Zimmermannova, Claire Schwab, Owen Smith, Marie-Joelle Mozziconacci, Christian Chabannon, Myungshin Kim, J. H. Frederik Falkenburg, Alice Norton, Karen Marshall, Oskar A. Haas, Julia Starkova, Jan Stuchly, Stephen P. Hunger, Deborah White, Charles G. Mullighan, Cheryl L. Willman, Jan Stary, Jan Trka, and Jan Zuna
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
To characterize the incidence, clinical features and genetics of ETV6-ABL1 leukemias, representing targetable kinase-activating lesions, we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies [22 cases of acute lymphoblastic leukemia (13 children, 9 adults) and 22 myeloid malignancies (18 myeloproliferative neoplasms, 4 acute myeloid leukemias)]. The presence of the ETV6-ABL1 fusion was ascertained by cytogenetics, fluorescence in-situ hybridization, reverse transcriptase-polymerase chain reaction and RNA sequencing. Genomic and gene expression profiling was performed by single nucleotide polymorphism and expression arrays. Systematic screening of more than 4,500 cases revealed that in acute lymphoblastic leukemia ETV6-ABL1 is rare in childhood (0.17% cases) and slightly more common in adults (0.38%). There is no systematic screening of myeloproliferative neoplasms; however, the number of ETV6-ABL1-positive cases and the relative incidence of acute lymphoblastic leukemia and myeloproliferative neoplasms suggest that in adulthood ETV6-ABL1 is more common in BCR-ABL1-negative chronic myeloid leukemia-like myeloproliferations than in acute lymphoblastic leukemia. The genomic profile of ETV6-ABL1 acute lymphoblastic leukemia resembled that of BCR-ABL1 and BCR-ABL1-like cases with 80% of patients having concurrent CDKN2A/B and IKZF1 deletions. In the gene expression profiling all the ETV6-ABL1-positive samples clustered in close vicinity to BCR-ABL1 cases. All but one of the cases of ETV6-ABL1 acute lymphoblastic leukemia were classified as BCR-ABL1-like by a standardized assay. Over 60% of patients died, irrespectively of the disease or age subgroup examined. In conclusion, ETV6-ABL1 fusion occurs in both lymphoid and myeloid leukemias; the genomic profile and clinical behavior resemble BCR-ABL1-positive malignancies, including the unfavorable prognosis, particularly of acute leukemias. The poor outcome suggests that treatment with tyrosine kinase inhibitors should be considered for patients with this fusion.
- Published
- 2016
- Full Text
- View/download PDF
22. Rapid Biomedical Research Classification: The Pandemic PACT Advanced Categorisation Engine.
- Author
-
Omid Rohanian, Mohammadmahdi Nouriborji, Olena Seminog, Rodrigo Furst, Thomas Mendy, Shanthi Levanita, Zaharat Kadri-Alabi, Nusrat Jabin, Daniela Toale, Georgina S. Humphreys, Emilia Antonio, Adrian Bucher, Alice Norton, and David A. Clifton
- Published
- 2024
- Full Text
- View/download PDF
23. Star Born
- Author
-
Andre Alice Norton and Andre Alice Norton
- Published
- 2022
24. The Time Traders
- Author
-
Andre Alice Norton and Andre Alice Norton
- Published
- 2021
25. Survival Outcomes of Children with Relapsed or Refractory Myeloid Leukemia Associated with Down syndrome
- Author
-
Nikhil Raghuram, Kentaro Nakashima, Syaza Ab Rahman, Evangelia Antoniou, Torjus Skajaa, Pietro Merli, Anupam Verma, Karen R. Rabin, Catherine Aftandilian, Rishi Sury Kotecha, Daniel Ka Leung Cheuk, Kirsi Jahnukainen, Alexandra Kolenova, Walentyna Balwierz, Alice Norton, Maureen M O'Brien, Sonia Cellot, Ashley Chopek, Nira Arad-Cohen, Bianca F. Goemans, Marta Rojas-Vasquez, Hany Ariffin, Jack Bartram, Edward A Kolb, Franco Locatelli, Daisuke Hasegawa, Jan-Henning Klusmann, Henrik Hasle, Bryan McGuire, Lillian Sung, and Johann K. Hitzler
- Subjects
Hematology - Abstract
Children with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population. We conducted a retrospective analysis of international study groups and pediatric oncology centers and identified 62 patients who received treatment with curative intent for r/r ML-DS between 2000-2021. Median time from diagnosis to relapse was 6.8 (range 1.1 - 45.5) months. Three-year event-free (EFS) and overall survival (OS) were 20.9±5.3% and 22.1±5.4%, respectively. Survival was associated with receipt of hematopoietic stem cell transplantation (HSCT) (HR 0.28), duration of first complete remission (CR1) (HR 0.31 for > 12 months) and attainment of remission after relapse (HR 4.03). Patients who achieved CR prior to HSCT, had an improved OS and EFS of 56.0±11.8% and 50.5±11.9% respectively, compared to those who underwent HSCT without CR (3-year OS and EFS of 10.0±9.5%). Treatment failure after HSCT was predominantly due to disease recurrence (52%) followed by treatment related mortality (10%). The prognosis of r/r ML-DS remains dismal even in the current treatment period and serve as a reference point for current prognostication and future interventional studies. Clinical trials aimed at improving the survival of patients with r/r ML-DS are needed.
- Published
- 2023
26. Scoping review protocol on research prioritisation for preparedness and response to outbreaks of high consequence pathogens
- Author
-
Emilia Antonio, Dorothy Chepkirui, Shanthi Levanita, Susan Khader Ibrahim, Isabel Foster, Eli Harriss, Louise Sigfrid, and Alice Norton
- Subjects
Study Protocol ,Preparedness ,Priority pathogens ,High consequence pathogens ,Response ,Articles ,General Medicine ,Research prioritisation - Abstract
Background: Prioritisation of research activities for infectious disease pathogens is usually undertaken through the identification of important research and knowledge gaps. Research prioritisation is an essential element of both effective responses to disease outbreaks and adequate preparedness. There is however currently no published mapping of activities on and evidence from research prioritisation for high consequence pathogens. The objectives of this review are to map all published research prioritisation exercises on high-consequence pathogens; provide an overview of methodologies employed for prioritising research for these pathogens; describe monitoring and evaluation processes for research areas prioritised; and identify any standards and guidance for effectively undertaking research prioritisation activities for high consequence pathogens. Methods: The Joanna Briggs Institute guidance of scoping review conduct will be used. The search will be undertaken using the key terms of “research prioritisation”, “response”, “control”, and related terms, and a list of high-consequence pathogens derived from WHO (2020), EMERGE (2019), Europe CDC (2022) and the Association of Southeast Asian Nations (2021). We will search WHO Global Index Medicus; Ovid Medline; Ovid Embase; Ovid Global Health; and Scopus. Backward citations review of the included full text documents will also be conducted. Google Scholar and Overton will be searched for grey literature. Two independent reviewers will screen the retrieved documents using Rayyan and extract data in a data extraction template in Microsoft Excel 2021. Screening results will be presented using the PRISMA-ScR template with narrative synthesis undertaken for the extracted data. Conclusion: This review will map existing research priorities for high consequence pathogens. Further, it will provide an understanding of methodologies used for prioritisation, processes for monitoring and evaluation of progress made against research agendas, and evidence on standards that could be recommended for effective prioritisation of research for high consequence pathogens.
- Published
- 2023
27. Research priorities for Long Covid: refined through an international multi-stakeholder forum
- Author
-
Fernando Augusto Bozza, Daniel Munblit, Jean Marie Vianney Habarugira, Alice Norton, Louise Sigfrid, Angela M. Cheung, Margaret Herridge, Andre Siqueira, Chris Brightling, Charitini Stavropoulou, Simone Piva, and Group, Long Covid Forum
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Consensus Development Conferences as Topic ,International Cooperation ,lcsh:Medicine ,Acute respiratory distress ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Post-Acute COVID-19 Syndrome ,Stakeholder Participation ,RA0421 ,GloPID-R ,medicine ,Humans ,030212 general & internal medicine ,Multi stakeholder ,Intensive care medicine ,WHO R&D COVID-19 Research Agenda ,Long Covid ,Long Covid Support Group ,Coronavirus research ,business.industry ,SARS-CoV-2 ,Research ,lcsh:R ,ISARIC ,COVID-19 ,General Medicine ,Infectious disease (medical specialty) ,Preparedness ,Commentary ,Tissue hypoxia ,medicine.symptom ,business ,RA ,030217 neurology & neurosurgery - Abstract
Coronavirus disease 2019 (COVID-19) can lead to a diverse range of clinical manifestations, ranging from an asymptomatic infection to an acute respiratory distress syndrome, and multiorgan failure with high mortality rates [1]. It is established that SARS-CoV-2 not only infects the respiratory tract but that the ensuing viral replication and immune response also affects multiple organ systems, in addition to an acute systemic inflammatory response and in some cases accompanying tissue hypoxia and shock.\ud \ud While many who have been infected have uncomplicated recoveries, some have prolonged illness. Prolonged course of illness has been reported in adults and children and is affecting both those who were hospitalised with COVID-19 and those who were not [2,3,4,5,6,7].\ud \ud In December 2020 ISARIC (the International Severe Acute Respiratory and emerging Infection Consortium), the research funders group GloPID-R (The Global Research Collaboration for Infectious Disease Preparedness) and global group, Long Covid Support, jointly organised a ‘Long Covid Forum’ [8]. This public forum aimed to gain a better understanding of ‘Long Covid’ and to define research priorities for funders and researchers to take forward.
- Published
- 2021
28. A living mapping review for COVID-19 funded research projects: two year update
- Author
-
Adrian Bucher, Emilia Antonio, Henrike Grund, Nusrat Jabin, Chantel Jones, Meron Kifle, Susan Khader, Genevieve Boily-Larouche, Morgan Lay, and Alice Norton
- Subjects
Medicine (miscellaneous) ,General Biochemistry, Genetics and Molecular Biology - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th July 2022 the database contains 17,955 projects, funded by 345 funders, taking place across 157 countries representing an investment of at least $6.5 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version nine analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version eight) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources and review investments.
- Published
- 2023
29. Priorities for COVID-19 research response and preparedness in low-resource settings
- Author
-
Alice Norton, Charu Kaushic, Julie Elise Archer, Moses Alobo, Marta Tufet Bayona, Caesar Alimsinya Atuire, Jean Marie Vianney Habarugira, Brenda Gloria Amo Okware, Helen Rees, Hans Eckhardt Hagen, Charles Shey Wiysonge, Nicholas J. White, Mohammad Abul Faiz, Francine Ntoumi, Akhona Tshangela, Gail Carson, Rui M.B. Maciel, Richard Vaux, Uma Ramakrishnan, Stefanie Sowinski, Rachel Elizabeth Esther Miles, Valerie A. Snewin, Choong Min Ryu, Patricia J. Garcia, S. Mburu, and GloPID-R, UKCDR, and COVID-19 Clinical Research Coalition Cross-Working Group on COVID-19 Research in LMICs
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Low resource ,Research ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Comment ,COVID-19 ,Developing country ,General Medicine ,Preparedness ,Political science ,Environmental health ,Humans ,Epidemics ,Developing Countries - Published
- 2021
30. Preparing for a pandemic: highlighting themes for research funding and practice—perspectives from the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)
- Author
-
Gail Carson, Adeniyi Aderoba, Shelui Collinson, Josephine P. Golding, Yazdan Yazdanpanah, Louise Sigfrid, Evelyn Depoortere, Barbara Kerstiëns, Naima Nasir, Geneviève Boily-Larouche, Alice Norton, James A. Lee, and Peter Bannister
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Pandemic ,Preparedness ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,lcsh:R ,Epidemic ,COVID-19 ,lcsh:Medicine ,General Medicine ,Collaboration ,Clinical trial ,Clinical trials ,Infectious disease (medical specialty) ,Family medicine ,Commentary ,medicine ,business ,Cohorts - Published
- 2020
31. Sudan virus disease outbreak in Uganda: urgent research gaps
- Author
-
Susan Khader Ibrahim, Duduzile Edith Ndwandwe, Katherina Thomas, Louise Sigfrid, and Alice Norton
- Subjects
Health Policy ,Public Health, Environmental and Occupational Health ,Humans ,Uganda ,Evidence Gaps ,Hemorrhagic Fever, Ebola ,Antibodies, Viral ,Disease Outbreaks - Abstract
The Sudan ebolavirus (SUDV) outbreak highlights our ongoing vulnerability to re-emerging high-consequence infectious diseases. Although the Minister of health in Uganda has initiated public health measures in collaboration with neighbouring countries and with support of the WHO, cases have continued to spread to several regions including the capital. The ongoing transmission, uncertain case numbers and no licensed vaccine or therapeutics available are a cause for concern. We searched four databases for SUDV research using the search terms “SUDV”, “Sudan Virus” and “Ebola Sudan”. Our analysis identified only 20 SUDV research studies. Most were implemented in the USA and only one in Uganda. Nine studies were on therapeutics, eight on vaccines, one on diagnostics, one in one health and one in social science. Our data highlight a lack of SUDV research and an urgent need for investment to identify an effective vaccine, and optimal supportive care and therapeutic strategies for all at risk groups as a key research priority. Research investments should be prioritised into vaccines and treatment strategies that will be accessible to high-risk populations in affected regions during the outbreak, to protect populations, improve individual outcomes and facilitate outbreak control.
- Published
- 2022
32. A living mapping review for COVID-19 funded research projects: 21 month update
- Author
-
Adrian Bucher, Emilia Antonio, Henrike Grund, Nusrat Jabin, Chantel Jones, Meron Kifle, Susan Khader, Genevieve Boily-Larouche, Morgan Lay, and Alice Norton
- Subjects
Medicine (miscellaneous) ,General Biochemistry, Genetics and Molecular Biology - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th April 2022 the database contains 16,353 projects, funded by 319 funders, taking place across 157 countries representing an investment of at least $6.2 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version eight analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version seven) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2022
33. A living mapping review for COVID-19 funded research projects: 18 month update
- Author
-
Adrian Bucher, Emilia Antonio, Henrike Grund, Nusrat Jabin, Chantel Jones, Meron Kifle, Susan Khader, Genevieve Boily-Larouche, Morgan Lay, and Alice Norton
- Subjects
Medicine (miscellaneous) ,General Biochemistry, Genetics and Molecular Biology - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th January 2022 the database contains 14,778 projects, funded by 306 funders, taking place across 157 countries representing an investment of at least $5.7 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version seven analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version six) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2022
34. Strengthening the global effort on COVID-19 research
- Author
-
Yazdan Yazdanpanah, Peter Piot, Alice Norton, Marta Tufet Bayona, and Jeffrey Mphahlele
- Subjects
medicine.medical_specialty ,Biomedical Research ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,International Cooperation ,Pneumonia, Viral ,Information Dissemination ,MEDLINE ,Article ,Betacoronavirus ,Political science ,Research Support as Topic ,medicine ,Humans ,Intensive care medicine ,Pandemics ,Health policy ,biology ,Viral Epidemiology ,Health Priorities ,SARS-CoV-2 ,Health Policy ,COVID-19 ,General Medicine ,medicine.disease ,biology.organism_classification ,Pneumonia ,Coronavirus Infections - Published
- 2021
35. Long COVID: tackling a multifaceted condition requires a multidisciplinary approach
- Author
-
Louise Sigfrid, Margaret E O’Hara, Charu Kaushic, Claire E. Hastie, Gail Carson, Piero Olliaro, Geneviève Boily-Larouche, Giuseppe Paparella, Jake Suett, and Alice Norton
- Subjects
Patient Care Team ,2019-20 coronavirus outbreak ,Patient care team ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Clinical Laboratory Techniques ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,MEDLINE ,COVID-19 ,medicine.disease ,Prognosis ,Corrections ,Betacoronavirus ,Infectious Diseases ,COVID-19 Testing ,Multidisciplinary approach ,Correspondence ,Medicine ,Humans ,Medical emergency ,business ,Coronavirus Infections ,Pandemics - Published
- 2021
36. The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults
- Author
-
Persis Amrolia, Jeanette Payne, Simone Stockley, Ajay Vora, Susan Baird, Michelle Cummins, Sara Ghorashian, Denise Bonney, John Moppett, Giorgio Ottaviano, Pamela Evans, Alice Norton, Philip Connor, Amrana Qureshi, Brenda Gibson, R Hough, Waseem Qasim, Danielle Ingham, Donna Lancaster, and Anne M. Kelly
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,business.industry ,medicine.medical_treatment ,MEDLINE ,Hematology ,Immunotherapy ,Survival Analysis ,United Kingdom ,Young Adult ,Refractory ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Medicine ,Lymphoblastic leukaemia ,Humans ,Female ,Young adult ,Neoplasm Recurrence, Local ,business ,Child ,Ireland - Published
- 2020
37. A living mapping review for COVID-19 funded research projects: one year update
- Author
-
Alice Norton, Adrian Bucher, Emilia Antonio, Nicole Advani, Cathryn Johnston, Henrike Grund, Sheila Mburu, Emma Clegg, Marguerite Gollish, Sara Sahota, Nusrat Jabin, Laura Scott, Genevieve Boily-Larouche, A. Morgan Lay, Gail Carson, and Marta Tufet Bayona
- Subjects
Medicine (miscellaneous) ,General Biochemistry, Genetics and Molecular Biology - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th July 2021 the database contains 12,419 projects, funded by 255 funders, taking place across 149 countries representing an investment of at least $4.9 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version five analysis we provide an updated detailed descriptive analysis of the database (three months after version four) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2022
38. Baseline results of a living systematic review for COVID-19 funded research projects
- Author
-
N. Advani, E. Clegg, Gail Carson, Alice Norton, S. Mburu, M. Tufet Bayona, Adrian Bucher, Emilia Antonio, H. Grund, A. M. Lay, and Geneviève Boily-Larouche
- Subjects
Gerontology ,0303 health sciences ,coordination ,Coronavirus disease 2019 (COVID-19) ,Medicine (miscellaneous) ,COVID-19 ,Articles ,General Biochemistry, Genetics and Molecular Biology ,research funding ,3. Good health ,Coronavirus ,03 medical and health sciences ,0302 clinical medicine ,Political science ,global health policy ,Living systematic review ,030212 general & internal medicine ,Systematic Review ,Baseline (configuration management) ,030304 developmental biology - Abstract
Background:The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims.Methods:The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15thJuly 2020 the database contains 1,858 projects, funded by 25 funders, taking place across 102 countries. To our knowledge it is one of the most comprehensive databases, covering a wide breadth of research disciplines. The database is aligned to the World Health Organisation (WHO) Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers.This living systematic review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio.Results:In this baseline analysis we provide the first detailed descriptive analysis of the database and focus our thematic analysis on research gaps, study populations and research locations (with a focus on resource-limited countries).Conclusions:This living systematic review will help both funders and researchers to prioritise resources to underfunded areas where there is greatest research need and facilitate further strategic collaboration.
- Published
- 2020
39. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion
- Author
-
Simone Stokley, Donna Lancaster, Neha Bhatnagar, Deborah Richardson, Christine J. Harrison, Sujith Samarasinghe, Frederik W. van Delft, John Moppett, Katharine Patrick, Alice Norton, Claire Schwab, Brenda Gibson, Emily Winterman, Anna Castleton, Pamela Kearns, Beki James, Andrew McMillan, Mabrouk S. Madi, Michelle Cummins, Jayashree Motwani, Anthony V. Moorman, Aengus O'Marcaigh, Amrana Qureshi, Ajay Vora, Amy A Kirkwood, Gordon Taylor, Jerry Hancock, and Nick Goulden
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Neoplasm, Residual ,Adolescent ,Oncogene Proteins, Fusion ,medicine.drug_class ,medicine.medical_treatment ,Tyrosine-kinase inhibitor ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Relapse risk ,Child ,Proto-Oncogene Proteins c-abl ,Protein Kinase Inhibitors ,Chemotherapy ,ABL ,business.industry ,Infant ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,respiratory tract diseases ,030220 oncology & carcinogenesis ,Child, Preschool ,Lymphoblastic leukaemia ,Female ,business ,Adjuvant ,Tyrosine kinase ,030215 immunology - Abstract
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).
- Published
- 2020
40. The remaining unknowns: A mixed methods study of the current and global health research priorities for COVID-19
- Author
-
Nicole Feune de Colombi, Juliette Mutheu Asego, Zainab Al-Rawni, Moses Alobo, Emilia Antonio, Wayne Mwangi, Marta Tufet, Arancha De La Horra Gozalo, Trudie Lang, Colette Adhiambo Wesonga, Peter Piot, Alice Norton, Kevin Marsh, and James S. Parker
- Subjects
Civil society ,medicine.medical_specialty ,Biomedical Research ,Pneumonia, Viral ,Disease ,other study design ,Global Health ,lcsh:Infectious and parasitic diseases ,Betacoronavirus ,Political science ,Pandemic ,Health care ,Global health ,medicine ,Humans ,lcsh:RC109-216 ,Pandemics ,Original Research ,other infection ,lcsh:R5-920 ,disease ,SARS-CoV-2 ,business.industry ,Health Policy ,Research ,Public health ,public health ,Public Health, Environmental and Occupational Health ,COVID-19 ,disorder ,Public relations ,Variety (cybernetics) ,or injury ,Work (electrical) ,Public trust ,Thematic analysis ,lcsh:Medicine (General) ,Coronavirus Infections ,business - Abstract
IntroductionIn March 2020 the World Health Organisation (WHO) released a Global Research Roadmap in an effort to coordinate and accelerate the global research response to combat COVID-19 based on deliberations of 400 experts across the world. Three months on, the disease and our understanding have both evolved significantly. As we now tackle a pandemic in very different contexts and with increased knowledge, we sought to build on the work of the WHO to gain a more current and global perspective on these initial priorities.MethodsWe undertook a mixed methods study seeking the views of the global research community to i) assess which of the early WHO roadmap priorities are still most pressing; ii) understand whether they are still valid in different settings, regions or countries; and iii) identify any new emerging priorities.ResultsThematic analysis of the significant body of combined data shows the WHO roadmap is globally relevant, however, new important priorities have emerged, in particular, pertinent to low and lower-middle income countries (less resourced countries), where health systems are under significant competing pressures. We also found a shift from prioritising vaccine and therapeutic development towards a focus on assessing the effectiveness, risks, benefits and trust in the variety of public health interventions and measures. Our findings also provide insight into temporal nature of these research priorities, highlighting the urgency of research that can only be undertaken within the period of virus transmission, as well as other important research questions but which can be answered outside the transmission period. Both types of studies are key to help combat this pandemic but also importantly to ensure we are better prepared for the future.ConclusionWe hope these findings will help guide decision making across the broad research system including the multi-lateral partners, research funders, public health practitioners, clinicians and civil society.Summary boxWhat is already known?The WHO produced a roadmap that set out the research priorities following a meeting in February, just before COVID-19 was declared a Pandemic. Now, at this point in the evolution of this novel disease across the world, and almost 6 months later, it is important to assess whether these priorities remain and if research teams in all countries across the globe agree that these are the most important question that need to be tackled within their health care setting and communities, both to mitigate this outbreak and to learn for next time.What are the new findings?Over 3,000 healthcare workers and researchers contributed to this research and their data tells us that across the globe there has been a shift in priorities and new questions have emerged, particularly from low-resourced settings. For example, there is a strong call for evidence on the relative effectiveness and optimal implementation of public health interventions in varied global settings, for social science studies to guide how to gain public trust and mitigate myths, to understand the impact on already present diseases within communities, and to explore the ethics of research within a pandemic.What do the new findings imply?The WHO roadmap is globally relevant, however, our findings also provide insight into the temporal nature of these research priorities, highlighting the urgency of research that can only be undertaken within the period of virus transmission, as well as other important research questions but which can be answered outside the transmission period. Both types of studies are key to help combat this pandemic but also importantly to ensure we are better prepared for the future.
- Published
- 2020
41. Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic ERCC6L2 variants
- Author
-
Jasmin K Sidhu, Michael Kirwan, Alice Norton, Matthew W Jenner, Helen Enright, Amanda J. Walne, Nikolas Pontikos, Ahad F. Al Seraihi, Tekin Aksu, Owen P. Smith, Isobel Browne, Alicia Ellison, Inderjeet Dokal, Pedro R. Cutillas, Tom Vulliamy, Vinothini Rajeeve, Hemanth Tummala, Namik Ozbek, Ana Rio-Machin, Saranha Amirthasigamanipillai, Shirleny Cardoso, Andrew S Duncombe, and Arran Dokal
- Subjects
0301 basic medicine ,Genome instability ,Multidisciplinary ,biology ,DNA repair ,RNA ,RNA polymerase II ,Molecular biology ,03 medical and health sciences ,030104 developmental biology ,Transcription (biology) ,Transcription preinitiation complex ,biology.protein ,Gene ,Nucleotide excision repair - Abstract
Biallelic variants in the ERCC excision repair 6 like 2 gene (ERCC6L2) are known to cause bone marrow failure (BMF) due to defects in DNA repair and mitochondrial function. Here, we report on eight cases of BMF from five families harboring biallelic variants in ERCC6L2, two of whom present with myelodysplasia. We confirm that ERCC6L2 patients' lymphoblastoid cell lines (LCLs) are hypersensitive to DNA-damaging agents that specifically activate the transcription coupled nucleotide excision repair (TCNER) pathway. Interestingly, patients' LCLs are also hypersensitive to transcription inhibitors that interfere with RNA polymerase II (RNA Pol II) and display an abnormal delay in transcription recovery. Using affinity-based mass spectrometry we found that ERCC6L2 interacts with DNA-dependent protein kinase (DNA-PK), a regulatory component of the RNA Pol II transcription complex. Chromatin immunoprecipitation PCR studies revealed ERCC6L2 occupancy on gene bodies along with RNA Pol II and DNA-PK. Patients' LCLs fail to terminate transcript elongation accurately upon DNA damage and display a significant increase in nuclear DNA-RNA hybrids (R loops). Collectively, we conclude that ERCC6L2 is involved in regulating RNA Pol II-mediated transcription via its interaction with DNA-PK to resolve R loops and minimize transcription-associated genome instability. The inherited BMF syndrome caused by biallelic variants in ERCC6L2 can be considered as a primary transcription deficiency rather than a DNA repair defect.
- Published
- 2018
42. Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome
- Author
-
Oliver Tunstall, Beki James, Alice Norton, Paresh Vyas, Irene Roberts, Aengus O'Marcaigh, Neha Bhatnagar, Michael T. Wright, Anne Greenough, and Timothy Watts
- Subjects
0301 basic medicine ,Antimetabolites, Antineoplastic ,Down syndrome ,medicine.medical_specialty ,Neoplasm, Residual ,Critical Illness ,DNA Mutational Analysis ,Exchange Transfusion, Whole Blood ,Leukemoid Reaction ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Recurrence ,Risk Factors ,Prenatal Diagnosis ,Transient Myeloproliferative Disorder ,Internal medicine ,Humans ,Medicine ,GATA1 Transcription Factor ,Leukapheresis ,business.industry ,Liver Diseases ,Transient abnormal myelopoiesis ,Cytarabine ,Hematology ,Prognosis ,medicine.disease ,Blood Cell Count ,Fetal Diseases ,Cell Transformation, Neoplastic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Cardiology ,Female ,Transient (oscillation) ,Down Syndrome ,business - Abstract
Methodology This guideline was compiled according to the British Society for Haematology (BSH) process at (http://www.bcshguidelines.com). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. Literature review details Ovid MEDLINE and Ovid EMBASE were searched systematically for publications in English from 1980 to the end of 2015 using the key words Transient Abnormal Myelopoiesis, Transient Myeloproliferative Disorder, Transient Leukaemia, and Down Syndrome. Specific searches relating to fetal disease and hepatic parameters were also performed. References from relevant publications were also searched. Working group membership The guideline group was selected to be representative of UK‐based medical experts with invited representatives from the British Association of Perinatal Medicine and the Royal College of Paediatrics and Child Health. Review Review of the manuscript was performed by the BSH Guidelines General Haematology Task Force, the BSH Guidelines Committee and the General Haematology sounding board of BSH. It was also placed on the members section of the BSH website for comment. Further comments were invited from a sounding board of the Childhood Leukaemia Clinicians'27 Network, the Childhood Cancer and Leukaemia Group (CCLG), the Royal College of Paediatrics and Child Health, the British Association of Perinatal Medicine (BAPM) and patient representatives identified through the Down Syndrome Association; these organisations do not necessarily approve or endorse the contents. The objective of this guideline is to provide healthcare professionals with guidance on the investigation and management of patients with Transient Leukaemia of Down Syndrome (TL‐DS). Individual patient circumstances may dictate an alternative approach. This is the first BSH guideline on this topic and is in date at time of publication. Any updates will be posted on the BSH Guidelines website (http://www.bcshguidelines.com).
- Published
- 2018
43. A living mapping review for COVID-19 funded research projects: nine-month update
- Author
-
Adrian Bucher, H. Grund, A. M. Lay, Alice Norton, Geneviève Boily-Larouche, N. Jabin, Emilia Antonio, E. Clegg, Gail Carson, N. Advani, L. Scott, M. Gollish, S. Mburu, and M. Tufet Bayona
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030231 tropical medicine ,Medicine (miscellaneous) ,medicine.disease_cause ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Geography ,Pandemic ,medicine ,030212 general & internal medicine ,Medical emergency ,Limited resources ,Coronavirus - Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th April 2021 the database contains 10,608 projects, funded by 201 funders, taking place across 142 countries representing an investment of at least $4.7 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version four analysis we provide an updated detailed descriptive analysis of the database (three months after version three) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2021
44. A living mapping review for COVID-19 funded research projects: six-month update
- Author
-
Alice Norton, Adrian Bucher, Emilia Antonio, Nicole Advani, Henrike Grund, Sheila Mburu, Emma Clegg, Marguerite Gollish, Nusrat Jabin, Laura Scott, Genevieve Boily-Larouche, A. Morgan Lay, Gail Carson, and Marta Tufet Bayona
- Subjects
03 medical and health sciences ,0302 clinical medicine ,030231 tropical medicine ,Medicine (miscellaneous) ,030212 general & internal medicine ,General Biochemistry, Genetics and Molecular Biology ,3. Good health - Abstract
Background:The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims.Methods:The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15thJanuary 2021 the database contains 7,778 projects, funded by 101 funders, taking place across 136 countries representing an investment of at least $3.8 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation (WHO) Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers.This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio.Results:In this version three analysis we provide an updated detailed descriptive analysis of the database (three months after version two) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries).Conclusions:As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
- Published
- 2021
45. Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic
- Author
-
Hemanth, Tummala, Arran D, Dokal, Amanda, Walne, Alicia, Ellison, Shirleny, Cardoso, Saranha, Amirthasigamanipillai, Michael, Kirwan, Isobel, Browne, Jasmin K, Sidhu, Vinothini, Rajeeve, Ana, Rio-Machin, Ahad Al, Seraihi, Andrew S, Duncombe, Matthew, Jenner, Owen P, Smith, Helen, Enright, Alice, Norton, Tekin, Aksu, Namık Yaşar, Özbek, Nikolas, Pontikos, Pedro, Cutillas, Inderjeet, Dokal, and Tom, Vulliamy
- Subjects
Male ,DNA Repair ,Transcription, Genetic ,DNA Helicases ,Genetic Diseases, Inborn ,DNA-Activated Protein Kinase ,Syndrome ,R loops ,Biological Sciences ,Genomic Instability ,DNA-PK ,A549 Cells ,Genetics ,Humans ,Female ,RNA Polymerase II ,ERCC6L2 ,transcription ,Bone Marrow Diseases ,Alleles ,HeLa Cells - Abstract
Significance Bone marrow failure (BMF) is an inherited life-threatening condition characterized by defective hematopoiesis, developmental abnormalities, and predisposition to cancer. BMF caused by ERCC6L2 mutations is considered to be a genome instability syndrome, because DNA repair is compromised in patient cells. In this study, we report BMF cases with biallelic disease-causing variants and provide evidence from patients’ cells that transcription deficiency can explain the genome instability. Specifically, we demonstrate that ERCC6L2 participates in RNA polymerase II-mediated transcription via interaction with DNA-dependent protein kinase (DNA-PK) and resolves DNA–RNA hybrids (R loops). Collectively, our data point to a causal mechanism in BMF in which patients with ERCC6L2 mutations are defective in the repair of transcription-associated DNA damage., Biallelic variants in the ERCC excision repair 6 like 2 gene (ERCC6L2) are known to cause bone marrow failure (BMF) due to defects in DNA repair and mitochondrial function. Here, we report on eight cases of BMF from five families harboring biallelic variants in ERCC6L2, two of whom present with myelodysplasia. We confirm that ERCC6L2 patients’ lymphoblastoid cell lines (LCLs) are hypersensitive to DNA-damaging agents that specifically activate the transcription coupled nucleotide excision repair (TCNER) pathway. Interestingly, patients’ LCLs are also hypersensitive to transcription inhibitors that interfere with RNA polymerase II (RNA Pol II) and display an abnormal delay in transcription recovery. Using affinity-based mass spectrometry we found that ERCC6L2 interacts with DNA-dependent protein kinase (DNA-PK), a regulatory component of the RNA Pol II transcription complex. Chromatin immunoprecipitation PCR studies revealed ERCC6L2 occupancy on gene bodies along with RNA Pol II and DNA-PK. Patients’ LCLs fail to terminate transcript elongation accurately upon DNA damage and display a significant increase in nuclear DNA–RNA hybrids (R loops). Collectively, we conclude that ERCC6L2 is involved in regulating RNA Pol II-mediated transcription via its interaction with DNA-PK to resolve R loops and minimize transcription-associated genome instability. The inherited BMF syndrome caused by biallelic variants in ERCC6L2 can be considered as a primary transcription deficiency rather than a DNA repair defect.
- Published
- 2018
46. Current and Experimental Treatments for Anxiety Disorders
- Author
-
Adam J. Guastella, Alice Norton, Gail A. Alvares, and Yun Ju Christine Song
- Abstract
There are currently a range of treatments available for anxiety disorders, including pharmacological and behavior-based therapies. The most widely used medications, for which there is considerable evidence of efficacy across a range of anxiety disorders, are the serotonin-selective reuptake inhibitor antidepressants. Benzodiazepines are also widely prescribed and show efficacy for acute anxiety, but their use in the treatment of chronic anxiety syndromes is more problematic. Many patients are not adequately covered by the available range of medications, which is driving interest in potentially new pharmacological approaches. The best established non-pharmacological treatment of anxiety is cognitive behavioral therapy and several related behavioral approaches, which have been shown to be efficacious in a range of anxiety disorders. One of these related approaches is called cognitive bias modification, which aims to alter an individual’s responses to anxiety-provoking stimuli.
- Published
- 2017
47. Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden
- Author
-
Prashant Hiwarkar, Alice Norton, Mark Velangi, Sanjeeva Gunasekera, Eleni Syrimi, and Jayashree Motwani
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Lysis ,Adolescent ,Urate Oxidase ,MEDLINE ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,medicine ,Rasburicase ,Humans ,030212 general & internal medicine ,Child ,Retrospective Studies ,business.industry ,Neoplasms therapy ,Infant ,Retrospective cohort study ,Hematology ,030220 oncology & carcinogenesis ,Child, Preschool ,Immunology ,Female ,business ,Tumor Lysis Syndrome ,medicine.drug - Published
- 2017
48. G387(P) More than just a toy: lego-induced epilepsy
- Author
-
A Sridharan, I Doughty, D. Ram, Timothy Martland, Alice Norton, and Trish Smith
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Seizure types ,Aura ,Audiology ,Stimulus (physiology) ,Electroencephalography ,medicine.disease ,Epilepsy ,Tongue biting ,Reflex Epilepsy ,medicine ,Cerebral function ,business - Abstract
Introduction Reflex epilepsy is a condition in which seizures can be provoked by an external stimulus. We present a very rare case of Lego-induced reflex epilepsy. Case A previously well 12 year old boy attended emergency services having been found unconscious by his parents among a pile of Lego. He had no tongue biting, incontinence or preceding aura. He subsequently had three further witnessed generalised seizures, all while playing with Lego. Multiple investigations including ECG, brain MRI and standard EEG were normal. However, a sleep-deprived EEG showed epileptiform activity while playing with Lego. Sodium valproate was commenced and he continued to play with Lego without seizures. On stopping Valproate at the age of 17, he had a further Lego-induced seizure. As he was keen to continue playing with Lego, he recommenced his medication. Just prior to recommencement, he interestingly had a seizure while solving a complex question during his AS level Mathematics Exam. He has remained seizure free since. Discussion The ILAE defines reflex epilepsy as seizures consistently resulting from a specific trigger, without spontaneous seizures otherwise. Triggers may be sensory (commonly photostimulatory) or related to higher cerebral functioning (in our case, related to praxis). To our knowledge, there is only one previous case report of Lego-induced epilepsy in literature. Complex patterns affecting higher cerebral function could explain both seizure types in our patient. Primary management involves removing the trigger. However, when this is not achievable, medical management should be considered. Conclusion The largest potential clues to diagnosis in reflex epilepsies are in history and examination, especially identifying a consistent trigger. Standard stimulation used during EEG recordings such as light and sound may not capture rarer reflex epilepsies. It is therefore vital to organise a concurrent EEG alongside the specific trigger wherever possible to clinch this rare diagnosis.
- Published
- 2017
49. The impact of single versus mixed Schistosoma haematobium and S. mansoni infections on morbidity profiles amongst school-children in Taveta, Kenya
- Author
-
Gerald M. Mkoji, Charles N. Lange, Alice Norton, Artemis Koukounari, Edmund Ireri, Anouk N. Gouvras, Joanne P. Webster, Curtis Kariuki, and Alan Fenwick
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Veterinary (miscellaneous) ,Urinary Bladder ,Schistosomiasis ,Physical examination ,Urine ,Praziquantel ,Schistosomiasis haematobia ,Young Adult ,Albumins ,Internal medicine ,parasitic diseases ,medicine ,Animals ,Humans ,Child ,Pathological ,Ultrasonography ,Anthelmintics ,Schistosoma haematobium ,biology ,medicine.diagnostic_test ,Coinfection ,Genitourinary system ,Schistosoma mansoni ,biology.organism_classification ,medicine.disease ,Kenya ,Schistosomiasis mansoni ,Human morbidity ,Cross-Sectional Studies ,Infectious Diseases ,Liver ,Child, Preschool ,Insect Science ,Immunology ,Female ,Parasitology ,Spleen ,medicine.drug - Abstract
Two schistosome species--Schistosoma haematobium and S. mansoni--with two very different pathological profiles (urogenital versus intestinal), are responsible for the majority of human schistosomiasis infections across sub-Saharan Africa. The aim of this study was to determine whether coinfections have an impact on species-specific morbidity measures when compared to single species infections. Children from two neighbouring schools in Taveta, Kenya were grouped by infection status, i.e. uninfected, single species infections or coinfected. Clinical examination of the liver and spleen by palpation was performed and urinary albumin levels were recorded at baseline and at 12 months after praziquantel administration. Additional ultrasonographic profiles of the children's liver, spleen and bladder were incorporated at follow-up. It was found that S. haematobium-associated urogenital morbidity was lower in the coinfected group relative to single S. haematobium infections, even when infection intensities were taken into account. We also observed an association between S. haematobium infection and liver (intestinal-associated) morbidity regardless of coinfections. The findings reported here suggest that further research should be performed on the impact of S. haematobium infections on liver morbidity as well as to determine the impact of mixed schistosome species infections on human morbidity outcomes across different endemic settings.
- Published
- 2013
50. Ralestone Luck
- Author
-
Andre Alice Norton and Andre Alice Norton
- Abstract
Rupert Ralestone is officially the Marquess of Lorne - but with no family money or prestige, the title is worthless. He and his younger brother and sister return to the old family homestead - Pirate's Haven. Their only hope is to find the sword that was the family's talisman for generations, the Ralestone Luck, and restore it to its proper place. If they succeed, the family fortunes will follow.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.